肌醇在多囊卵巢综合征中的治疗临床应用现状

Therapeutic effect and mechanism of the inositol in polycystic ovary syndrome

多囊卵巢综合征(polycystic ovary syndrome,PCOS)是最常见的妇科内分泌疾病之一,以高雄激素、持续无排卵和胰岛素抵抗(IR)为特征,是导致女性不孕的主要原因之一。肌肉肌醇(MI)和D-手性肌醇(DCI)为两种肌醇异构体,可通过改善IR、降低雄激素和改善代谢,以及降低氧化应激对PCOS有治疗作用。然而,仅使用大剂量的DCI对卵子质量反而有不利影响。近年来,越来越多的研究表明,MI和DCI联合应用,以40:1的生理剂量比例治疗PCOS效果更为显著。现对肌醇在PCOS中的治疗作用及其机制作一综述。

Polycystic ovary syndrome（PCOS） is the most common endocrine disorder and is one of the leading cause of female infertility, characterized by hyperandrogenism, chronic anovulation and insulin resistance（IR）. Myoinositol（MI） and D-chiro-inositol（DCI） which are two inositol isomers have been proven to be effective in PCOS treatment, by improving the IR, androgen and metabolism, reducing oxidative stress（OS） damage. However, only using large dose of DCI have an adverse effect on oocyte quality. In recent years, more and more studies have shown that the combined administration of MI and DCI in the physiological plasma ratio（40 ： 1）, could be have more remarkable effect. Here we review the role and mechanism of inositol in PCOS.